Skip to main content
SpringerLink
Log in

Fluorine- 18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: Preliminary results

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objectives

We compared the diagnostic value of fluorine-18-fiuorodeoxyglucose positron emission tomography (FDG-PET) with that of computed tomography (CT) following radiofrequency ablation (RFA) of inoperable recurrent or metastatic cancers in the lung.

Methods

Twelve patients (9 males and 3 females; 5 had recurrent lung cancer and the other 7 had metastatic nodules from a variety of primary cancers) were treated by RFA for 17 pulmonary nodules. FDG-PET was performed before and 2 months after RFA, and the mean standardized uptake value (SUV) was calculated. The response evaluation was based on the percent reduction relative to the baseline and the absolute values of SUV on FDG-PET performed at 2 months after RFA. We compared the response evaluations made based on findings of FDG-PET and CT at 2 and ≥6 months (mean 10.2) after RFA.

Results

The percent reduction in uptake at 2 months was significantly lower in nodules considered progressive (69.6± 18.6%) than nonprogressive disease (38.7 ± 12.5%; p < 0.01) based on CT findings at >6 months after RFA. The absolute SUV at 2 months was significantly higher in nodules considered progressive (2.61 ±0.75) than nonprogressive disease (1.05 ±0.67; p<0.01) based on CT findings at ≥6 months post-RFA.

Conclusion

Although our pilot study comprised few cases of various histopathological types of cancers in the lung, the results suggest that FDG-PET could predict regrowth on subsequent follow-up CT. Regrowth could be diagnosed earlier by FDG-PET than by CT, and nodules with residual uptake and with <60% reduction of uptake relative to baseline on FDG-PET at 2 months after ablation might require additional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy.Radiology 2000; 217:633–646.

    PubMed  CAS  Google Scholar 

  2. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities—part 2.J Vasc Interv Radiol 2001; 12:1135–1148.

    Article  PubMed  CAS  Google Scholar 

  3. Curley SA, Izzo F, Ellis LM, Nicolas VJ, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.Ann Surg 2000; 232:381–391.

    Article  PubMed  CAS  Google Scholar 

  4. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.Radiology 2000; 214:761–768.

    PubMed  CAS  Google Scholar 

  5. Rossi S, DiStasi M, Buscarini E, Quaretti P, Garbgnati F,Squassante L, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.AJR Am J Roentgenol 1996; 167:759–768.

    PubMed  CAS  Google Scholar 

  6. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors.Radiology 2003; 226:417–424.

    Article  PubMed  Google Scholar 

  7. Rosenthal DI, Springfield DS, Gebhart MC, Rosenberg AE, Mankin HJ. Osteoid osteoma: percutaneous radio-frequency ablation.Radiology 1995; 197:451–454.

    PubMed  CAS  Google Scholar 

  8. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, et al. Percutaneous radiofrequency ablation of malignancies in the lung.AJR Am J Roentgenol 2000; 174:57–59.

    PubMed  CAS  Google Scholar 

  9. Steinke K, Habicht JM, Thomsen S, Soler M, Jacob AL. CT-guided radiofrequency ablation of a pulmonary metastasis followed by surgical resection.Cardiovasc Intervent Radiol 2002; 25:543–546.

    Article  PubMed  Google Scholar 

  10. Herrera LJ, Fernando HC, Perry Y, Gooding WE, Buenaventura PO, Christie NA, et al. Radiofrequency ablation of pulmonary tumors in nonsurgical candidates.J Thorac Cardiovasc Surg 2003; 125:929–937.

    Article  PubMed  Google Scholar 

  11. Oyama M, Matsuoka T, Toyoshima M, Okuma T, Yamamoto A, Sakai Y, et al. Usefulness of computed tomography for evaluating recurrence after radiofrequency ablation.JJLC Jpn J Lung Cancer 2003; 43:247–252.

    Google Scholar 

  12. Steinke K, King J, Glenn D, Morris DL. Radiologic appearance and complications of percutaneous computed tomography-guided radiofrequency-ablated pulmonary metastases from colorectal carcinoma.J Comput Assist Tomogr 2003; 27:750–757.

    Article  PubMed  Google Scholar 

  13. Sewell PE, Jackson MS, Vance RB, Wang YD. Assessing radiofrequency ablation of non-small cell lung cancer with positron emission tomography (PET) [abstract].Radiology2000; 217(suppl):334.

    Google Scholar 

  14. Akeboshi M, Yamakado K, Nakatsuka A, Hataji O, Taguchi O, Takao M, et al. Percutaneous radiofrequency ablation of lung neoplasms: Initial therapeutic response.J Vasc Interv Radiol 2004; 15:463–470.

    PubMed  Google Scholar 

  15. Dupuy DE, Mayo-Smith WW, Abbott GF, DiPetrillo T. Clinical applications of radio-frequency tumor ablation in the thorax.RadioGraphics 2002; 22:S259–269.

    PubMed  Google Scholar 

  16. Suh RD, Wallace AB, Sheehan RE, Heinze SB, Goldin JG. Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation—Preliminary results.Radiology 2003; 229:821–829.

    Article  PubMed  Google Scholar 

  17. Matsuoka T, Toyoshima M, Nakamura K, Yamada R, Inoue K, Lubinski A. Percutaneous radiofrequency ablation for lung tumors.Cardiovasc Intervent Radiol 2001; 24 (suppl): 202.

    Article  Google Scholar 

  18. Yasui K, Kanazawa S, Sano Y, Fujiwara T, Kagawa S, Mimura H, et al. Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience.Radiology 2004; 231:850–857.

    Article  PubMed  Google Scholar 

  19. Nishida T, Inoue K, Kawata Y, Izumi N, Nishiyama N, Kinoshita H, et al. Percutaneous radiofrequency ablation of lung neoplasms: A minimally invasive strategy for inoperable patients.J Am Coll Surg 2002; 195:426–430.

    Article  PubMed  Google Scholar 

  20. Giannopoulou C. The role of SPET and PET monitoring tumour response to therapy.Eur J Nucl Med 2003; 30:1173–1200.

    Article  Google Scholar 

  21. Lee J, Aronchick JM, Alavi A. Accuracy of F-18 Fluoro-deoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities.Chest 2001; 120:1791–1797.

    Article  PubMed  CAS  Google Scholar 

  22. Kostakoglu L, Goldsmith SJ. F-18-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.J Nucl Med 2003; 44:224–239.

    PubMed  Google Scholar 

  23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst 2000; 92:205–216.

    Article  PubMed  CAS  Google Scholar 

  24. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection.Eur J Nucl Med 2001; 28:696–703.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiolgy, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, 545-8585, Abeno-ku, Osaka, Japan

    Tomohisa Okuma, Toshiyuki Matsuoka, Akira Yamamoto, Yoshimasa Oyama, Koichi Koyama, Kenji Nakamura & Yuichi Inoue

  2. Saiseikai Nakatsu PET Center Hospital, Japan

    Terue Okamura

  3. Department of Radiology, Kobe Nishi- shimin Hospital, Japan

    Masami Toyoshima

  4. Second Department of Surgery, Osaka City University Graduate School of Medicine, Japan

    Kiyotoshi Inoue

Authors
  1. Tomohisa Okuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terue Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshiyuki Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshimasa Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masami Toyoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koichi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kiyotoshi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenji Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuichi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomohisa Okuma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuma, T., Okamura, T., Matsuoka, T. et al. Fluorine- 18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: Preliminary results. Ann Nucl Med 20, 115–121 (2006). https://doi.org/10.1007/BF02985623

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02985623

Key words

Search

Navigation